<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925545</url>
  </required_header>
  <id_info>
    <org_study_id>CTP07700</org_study_id>
    <nct_id>NCT03925545</nct_id>
  </id_info>
  <brief_title>VisiOn Restoration With FluidVisION Accommodating Intraocular Lens (AIOL)</brief_title>
  <acronym>ORION</acronym>
  <official_title>VisiOn Restoration With the FluidVisION AIOL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PowerVision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PowerVision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to obtain an initial assessment of the safety and performance&#xD;
      of an investigational AIOL in patients undergoing cataract extraction and IOL implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was originally designed as a single arm, unilateral study (one eye, one product&#xD;
      only) to obtain an initial assessment of the safety and performance of an investigational IOL&#xD;
      in subjects undergoing cataract extraction and IOL implantation. The study design was later&#xD;
      modified to a contralateral study (both eyes, different product in each eye) to compare the&#xD;
      safety and performance of the investigational IOL to a commercially available monofocal IOL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2017</start_date>
  <completion_date type="Actual">November 27, 2018</completion_date>
  <primary_completion_date type="Actual">November 27, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accommodative Amplitude (AA)</measure>
    <time_frame>Month 6 postoperative</time_frame>
    <description>Accommodative amplitude is the ability of the eye to change its focus from distant to near objects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distance Corrected Visual Acuity</measure>
    <time_frame>Month 6 postoperative</time_frame>
    <description>Visual acuity was measured with distance correction (plus or minus power) in place.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>International Organization for Standardization (ISO)-defined Cumulative and Persistent Adverse Events for Posterior Chamber IOL</measure>
    <time_frame>Up to Month 6 postoperative</time_frame>
    <description>Adverse events were categorized per ISO 11979-7: Ophthalmic Implants - Intraocular Lenses - Part 7: Clinical Investigations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accommodative Amplitude</measure>
    <time_frame>Month 3 postoperative</time_frame>
    <description>Accommodative amplitude is a measure of the range of vision with good acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Add Power Required to Achieve Best Corrected Near Visual Acuity</measure>
    <time_frame>Up to Month 6 postoperative</time_frame>
    <description>Plus lenses were placed over the subject's best distance manifest correction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Visual Acuity</measure>
    <time_frame>Up to Month 6 postoperative</time_frame>
    <description>Visual acuity was measured without correction in place.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Unilateral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation with the FluidVision AIOL in one eye during cataract surgery. Only one eye was treated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Contralateral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation with the FluidVision AIOL in the first eye during cataract surgery, followed by implantation with the AcrySof IQ monofocal IOL in the fellow eye during a subsequent cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FluidVision AIOL</intervention_name>
    <description>Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject</description>
    <arm_group_label>Contralateral</arm_group_label>
    <arm_group_label>Unilateral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcrySof IQ monofocal IOL</intervention_name>
    <description>Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject</description>
    <arm_group_label>Contralateral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>Standard cataract extraction with phacoemulsification</description>
    <arm_group_label>Contralateral</arm_group_label>
    <arm_group_label>Unilateral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Corrected distance visual acuity (CDVA) worse than 20/40, or presence of visually&#xD;
             significant lens opacity;&#xD;
&#xD;
          -  Preoperative or predicted postoperative astigmatism of â‰¤ 1.0 diopter (D);&#xD;
&#xD;
          -  Calculated IOL power within range.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Current medication that may affect accommodation;&#xD;
&#xD;
          -  Systemic disease or concomitant medication that may increase operative risk or&#xD;
             confound results;&#xD;
&#xD;
          -  Ocular conditions that may predispose the subject for future complications;&#xD;
&#xD;
          -  Monocular subjects or subjects with significant permanent visual function loss in&#xD;
             fellow eye;&#xD;
&#xD;
          -  Previous intraocular or corneal surgery in either eye that may confound the results or&#xD;
             increase the risk to the subject, including implantation of a multifocal IOL or other&#xD;
             presbyopic corrective surgery in the fellow eye;&#xD;
&#xD;
          -  Grade 4 cataract of any type.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

